Pitt Team: KDM Inhibitors Dampen Macrophage Inflammation in Mouse, Cell Models

A team at the University of Pittsburgh reports in the Journal of Biological Chemistry that blocking lysine demethylases — enzymes that act as genetic “off switches” in macrophages — can quiet inflammation in cells and in mice.

The work offers a proof of concept for a macrophage-targeted anti-inflammatory therapy.

Macrophages are the immune system’s cleanup crew and first responders. As the study abstract describes, these innate immune cells detect and engulf bacteria, clear cellular debris and dying cells, and can flip between a pro-inflammatory state that fights infection and a reparative state that heals tissue. When that switch gets stuck in the “on” position, the result is the runaway inflammation seen in sepsis, severe influenza, and long COVID-19.

What the Pittsburgh group found is that this polarization — the shift between inflammatory and reparative identities — is governed by epigenetic enzymes that tag chromatin, the packaged form of DNA, with chemical marks. Lysine demethylases, or KDMs, remove inhibitory histone methylation marks during immune cell development, effectively freeing inflammatory genes to fire.

Why Immune Cell “Memory” Matters in Lung Disease

Using open-source datasets, the researchers found that KDM expression runs higher in alveolar macrophages — the air sac scavengers of the lung — from patients with long COVID-19 and bacterial sepsis, and in lung macrophages of mice with influenza. That pattern suggested the enzymes were not bystanders but active participants in inflammatory lung disease.

To test causation, the team screened a panel of small-molecule inhibitors of chromatin modifiers in laboratory-grown macrophages.

Pretreating bone marrow-derived macrophages with either n-octyl-IOX1, a broad-spectrum KDM inhibitor, or PB-IT, which specifically targets the KDM5 family, before exposing the cells to lipopolysaccharide — bacterial LPS, a potent inflammatory trigger — significantly reduced expression of the inflammatory genes Il1b, Il6, Tnfa, and iNos, according to the study record on Europe PMC. The treatment also dampened the Nlrp3 inflammasome, a protein complex that amplifies inflammatory responses.

Deeper sequencing work showed why. LPS activation rewired the cells’ regulatory networks, including expression of master transcription factors BLIMP-1 and GFI1; the two inhibitors reworked those networks again, impeding inflammatory gene expression. In plain terms, the drugs didn’t just mute one alarm — they changed which genetic programs the cell could access.

KDM Enzymes Keep Inflammatory Genes Open

  • Macrophages can be pushed into an inflammatory overdrive; a family of enzymes called KDMs helps hold the genes for that overdrive open.
  • Two experimental chemicals, n-octyl-IOX1 and PB-IT, closed those genes in lab-grown immune cells before inflammation began.
  • A nanoparticle delivery system steered the drug to macrophages in mice and reduced inflammatory gene expression there too — but this remains early animal and cell research, not an available treatment.

A Delivery System Aimed Only at Macrophages

Broadly suppressing inflammation is easy; doing so without disarming the body’s defenses is the hard part. The Pittsburgh team addressed this with lipidoid nanoparticles — fatty particles engineered to target specific cells — that encapsulated n-octyl-IOX1 and delivered it selectively to macrophages in mice. In the animals, the encapsulated drug significantly diminished LPS-driven peritoneal macrophage expansion and inflammatory gene expression in that cell population, the published paper reports.

That targeting matters because macrophages are double-edged: they clear pathogens and recruit other immune cells when needed, and they also resolve inflammation and promote wound healing. A therapy that hammers all macrophages indiscriminately could impair infection control. Cell-specific delivery is the design feature that separates this approach from older, blunter anti-inflammatory strategies.

Compound Target Tested setting Effect reported
n-octyl-IOX1 Broad-spectrum KDM inhibition Cells and mice Reduced inflammatory genes; reduced macrophage expansion in vivo
PB-IT KDM5-specific Cells Reduced LPS-induced inflammatory genes

From Bench to Bedside: Sepsis, Flu, and Long COVID

The authors frame this as proof of concept, not a clinical therapy. Future studies will evaluate whether the approach applies to sepsis, influenza-associated inflammation, and long COVID-19 — conditions where macrophage-driven lung inflammation remains a treatment gap. No human dosing, safety data, or trial timelines exist yet, and the translation from mouse peritoneal macrophages to patients with respiratory failure is a step many early-stage findings never complete.

Regulatory pathways would also be demanding. An epigenetic drug aimed at immune cells would need to demonstrate, in controlled trials, that it suppresses harmful inflammation without blunting host defense — a balance regulators such as the FDA and Europe’s EMA scrutinize closely in any immunomodulator.

The study itself, indexed on Europe PMC, comes from the Division of Cardiology at the University of Pittsburgh School of Medicine and the Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, with Niranjana Natarajan, Thaybah Ahmed, and Balaji Govindaswamy among the seven authors.

Funding sources for the work are not stated in the material published alongside the study, and the findings so far rest on in vitro experiments, transcriptomic datasets, and mouse models rather than human trials.

Patients Should Not Change Treatment Yet

Patients living with long COVID-19, recovering from sepsis, or managing recurrent respiratory infections should not alter treatment based on this research. Anyone experiencing persistent breathlessness, chest symptoms, or unexplained fever after an infection should consult a physician, who can evaluate for established conditions using current clinical guidelines.

Early-stage laboratory findings like these can stall or fail in human testing; the appropriate response is informed patience, not anticipation of a near-term drug.

The Takeaway: Rewriting Inflammation at the Chromatin Level

The significance here is conceptual as much as practical. Rather than blocking a single cytokine after it is released, the Pittsburgh approach edits the epigenetic permission slip that lets inflammatory genes be read in the first place — and aims the edit at the specific cells doing the damage.

Whether that precision survives contact with human biology is exactly what the researchers’ planned follow-up studies on sepsis, influenza, and long COVID-19 are designed to find out.

References

  • Natarajan, N., Ahmed, T., Govindaswamy, B., et al. “Macrophage-specific targeting of histone demethylases with small-molecule inhibitors suppresses inflammatory response in vivo.” Journal of Biological Chemistry, 2026. doi.org/10.1016/j.jbc.2026.113315
  • Study abstract and affiliation record, Europe PMC. europepmc.org/article/MED/42409265
  • American Society for Biochemistry and Molecular Biology, coverage of “Targeting lysine demethylases dampens inflammatory macrophages.”
Photo of author

Health Desk

Health Desk at Archyde.

NVIDIA Beats Q3 Forecasts but Stock Falls as Board Rejects Huang’s Return